Condition
Advanced Neuroendocrine Carcinoma
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05969860Phase 2Recruiting
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT07520357Phase 2Not Yet RecruitingPrimary
A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma
NCT06157827Phase 1RecruitingPrimary
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT05015621Phase 3UnknownPrimary
A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
Showing all 4 trials